GT BIOPHARMA INC

GT Biopharma’s 9.3% rally sparks caution: low volume, weak fundamentals, and a price far above its 200‑day SMA raise red flags for investors.

Gt Biopharma (GTBP) dips 4.84% as investors watch upcoming oncology trial data; despite volatility, the company’s niche platform offers potential upside if clinical milestones hit.